10 / 32
American Society
of Clinical Oncology
2017 Annual Meeting
2–6 JUNE 2017 • CHICAGO, USA
At this year’s ASCO annual
meeting, the PracticeUpdate
Editorial team spoke to some
of oncology’s most esteemed
minds for their thoughts
on key clinical trial data
presented at the meeting,
and those they considered
practice changers.
Practice changers in advanced prostate cancer:
STAMPEDE, LATITUDE vis-à-vis CHAARTED
Dr Farzanna Haffizulla speaks with Oliver A Sartor MD, Laborde
Professor in Cancer Research in the Medicine and Urology
Departments at Tulane School of Medicine in Louisiana, on the
STAMPEDE, LATITUDE and CHAARTED trials and what they
mean for men with prostate cancer.
Dr Haffizulla:
I wanted to talk about the most
recent data from STAMPEDE. We’re here at
ASCO 2017 and I know in STAMPEDE we’re
assessing abiraterone in the context of hor-
mone-sensitive prostate cancer. What does
this data mean for clinical practice?
Dr Sartor:
I think it’s practice changing.
The utilization of ADT has been ongo-
ing since 1941 and it’s sort of the standard
that we’ve become accustomed to. There
was a clinical trial called CHAARTED that
helped change that standard by adding
in chemotherapy and STAMPEDE had
another arm that added in chemotherapy.
But the new data is with abiraterone, and
it’s being compared against conventional
ADT. It’s really strikingly positive, and within
the metastatic subset almost a reduction of
40%; it’s like a 39% reduction in mortality.
It’s pretty reasonably well tolerated.
The PFS and other components of the
endpoints were all strikingly positive, and
I think it’s a practice changer. I think peo-
ple are going to be looking at abiraterone
with a low-dose prednisone, only 5 mg of
prednisone, add it to ADT as being a new
potential standard of care.
Dr Haffizulla:
How does this data differ from
LATITUDE?
Dr Sartor:
Well, the LATITUDE is a little bit
more restricted, so what I didn’t tell you
about STAMPEDE is it also took the non-
metastatic patients, and I personally feel
as though the nonmetastatic patients
don’t have adequate maturity to be con-
clusive. Their failure-free survival is very
strongly positive on the abiraterone, but
their overall survival and then the hazard
ratio was good at 0.75. Confidence level
is still big and not a lot of maturity in that.
So, STAMPEDE actually took in a lot of the
nonmetastatic patients.
CONFERENCE COVERAGE
10
PRACTICEUPDATE ONCOLOGY